Cargando…
Patient-tailored antithrombotic therapy following percutaneous coronary intervention
Dual antiplatelet therapy has long been the standard of care in preventing coronary and cerebrovascular thrombotic events in patients with chronic coronary syndrome and acute coronary syndrome undergoing percutaneous coronary intervention, but choosing the optimal treatment duration and composition...
Autores principales: | van der Sangen, Niels M R, Rozemeijer, Rik, Chan Pin Yin, Dean R P P, Valgimigli, Marco, Windecker, Stephan, James, Stefan K, Buccheri, Sergio, ten Berg, Jurriën M, Henriques, José P S, Voskuil, Michiel, Kikkert, Wouter J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244639/ https://www.ncbi.nlm.nih.gov/pubmed/33515031 http://dx.doi.org/10.1093/eurheartj/ehaa1097 |
Ejemplares similares
-
Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations
por: Kwon, Osung, et al.
Publicado: (2022) -
Antithrombotic therapy in diabetes: which, when, and for how long?
por: Ajjan, Ramzi A, et al.
Publicado: (2021) -
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk
por: Urban, Philip, et al.
Publicado: (2019) -
Oncometabolites: tailoring our genes
por: Nowicki, Stefan, et al.
Publicado: (2015) -
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)